2 FDA committee members resign over Biogen Alzheimer’s drug approval

Fallout over the FDA’s recent decision to grant Biogen’s Alzheimer’s drug accelerated approval has seen two advisory panel members resign. The agency’s decision, which was met with mixed reviews and…